智通财经APP获悉，私募股权巨头KKR集团(KKR.US)提议，以116亿瑞典克朗(约合12亿美元)收购瑞典生命科学企业Biotage的全部股份。
根据周二发布的声明，一家由KKR间接全资控股的新公司RWK BidCo开出每股145瑞典克朗的现金收购价，这一报价较Biotage股票上一交易日收盘价溢价60.1% 。
KKR表示，多年来一直密切关注Biotage的发展，并对其成就颇为赞赏。这种关注尤其体现在Gamma Biosciences公司与Biotage的关系上——Gamma Biosciences由KKR旗下基金控股，同时也是Biotage的最大股东。
Biotage董事会对KKR的收购提议进行评估后，已告知RWK BidCo，董事会将建议公司股东接受此次收购要约。
Biotage专注于基因分析和药物化学领域，为客户提供技术和解决方案。据其官网信息，公司拥有700名员工，业务覆盖全球80多个国家和地区。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.